Cargando…

Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial

BACKGROUND: Group B streptococcus (GBS) is a major cause of invasive disease in young infants. Infants born to women with sufficient pre-existing anti-GBS capsular IgG antibodies are at reduced risk of GBS disease, making maternal immunisation a potential strategy for prevention. We aimed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Absalon, Judith, Segall, Nathan, Block, Stan L, Center, Kimberly J, Scully, Ingrid L, Giardina, Peter C, Peterson, James, Watson, Wendy J, Gruber, William C, Jansen, Kathrin U, Peng, Yahong, Munson, Samantha, Pavliakova, Danka, Scott, Daniel A, Anderson, Annaliesa S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760110/ https://www.ncbi.nlm.nih.gov/pubmed/32891191 http://dx.doi.org/10.1016/S1473-3099(20)30478-3

Ejemplares similares

A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization
por: Buurman, Ed T, et al.
Publicado: (2019)

Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches
por: Absalon, Judith, et al.
Publicado: (2022)

Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Streptococcus pneumoniae Capsular Polysaccharides
por: Pavliakova, Danka, et al.
Publicado: (2018)

A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years
por: Kitchin, Nicholas, et al.
Publicado: (2020)

A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States
por: Fitz-Patrick, David, et al.
Publicado: (2021)

Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2021)

1236. Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2020)

Evaluation of Approaches to Monitor Staphylococcus aureus Virulence Factor Expression during Human Disease
por: Rozemeijer, Wouter, et al.
Publicado: (2015)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)

Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants
por: Wu, Zhiwei, et al.
Publicado: (2022)

A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age
por: Essink, Brandon, et al.
Publicado: (2021)

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years
por: Essink, Brandon, et al.
Publicado: (2021)

Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides
por: Tan, Charles Y., et al.
Publicado: (2018)

1728. Immune Responses to Cross-Reactive Serotypes 6C and 15C After 20-Valent Pneumococcal Conjugate Vaccine in Infants
por: Tamimi, Noor, et al.
Publicado: (2023)

Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine
por: Scully, Ingrid L., et al.
Publicado: (2014)

Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection
por: Anderson, Annaliesa S., et al.
Publicado: (2016)

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
por: Hurley, Donald, et al.
Publicado: (2020)

A Longitudinal Study of Group A Streptococcal Colonization and Pharyngitis in US Children
por: Frenck, Robert W., et al.
Publicado: (2023)

Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults
por: Inoue, Megumi, et al.
Publicado: (2018)

16. A Randomized Phase 1 Study of a Novel Pneumococcal Conjugate Vaccine in Healthy Japanese Adults in the United States
por: Fitz-Patrick, David, et al.
Publicado: (2020)

A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
por: Giambi, Cristina, et al.
Publicado: (2008)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
por: Sabharwal, Charu, et al.
Publicado: (2022)

Hexavalent chromium (Contaminants)
Publicado: (2019)

12. Randomized Studies of Two Clostridioides (Clostridium) difficile Vaccine Formulations
por: Lawrence, Jody, et al.
Publicado: (2020)

The impact of human vaccines on bacterial antimicrobial resistance. A review
por: Jansen, Kathrin U., et al.
Publicado: (2021)

Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa
por: Koen, Anthonet, et al.
Publicado: (2020)

1240. Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age
por: Hurley, Donald, et al.
Publicado: (2020)

Performance of a Four-Antigen Staphylococcus aureus Vaccine in Preclinical Models of Invasive S. aureus Disease
por: Scully, Ingrid L., et al.
Publicado: (2021)

The role of vaccines in fighting antimicrobial resistance (AMR)
por: Jansen, Kathrin U., et al.
Publicado: (2018)

3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older
por: Essink, Brandon, et al.
Publicado: (2020)

A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates
por: Stone, V. M., et al.
Publicado: (2020)

Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors
por: Anderson, Annaliesa S., et al.
Publicado: (2012)

Biosorption of hexavalent chromium by Pleurotus ostreatus
por: da Rocha Ferreira, Glalber Luiz, et al.
Publicado: (2019)

1337. Development, Maintenance, and Application of Opsonophagocytic Assays to Measure Functional Antibody Responses to Support a 20 Valent Pneumococcal Conjugate Vaccine
por: Scully, Ingrid L, et al.
Publicado: (2019)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

Generation and characterization of monospecific and bispecific hexavalent trimerbodies
por: Blanco-Toribio, Ana, et al.
Publicado: (2013)

Phytofabrication of Iron Nanoparticles for Hexavalent Chromium Remediation
por: Truskewycz, Adam, et al.
Publicado: (2018)

Adverse hematological effects of hexavalent chromium: an overview
por: Ray, Rina Rani
Publicado: (2016)

Immunogenicity and protective efficacy of a Streptococcus suis vaccine composed of six conserved immunogens
por: Weiße, Christine, et al.
Publicado: (2021)

Vaccination strategies for the prevention of meningococcal disease
por: Vuocolo, Scott, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fhoclnnmcfbmbodhaita6drqe2